SU-F-T-474: Evaluation of Dose Perturbation, Temperature and Sensitivity Variation With Accumulated Dose of MOSFET Detector

2016 ◽  
Vol 43 (6Part20) ◽  
pp. 3572-3572
Author(s):  
B Ganesan ◽  
A Prakasarao ◽  
T Palraj ◽  
R Rai ◽  
G Singaravelu
2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Yang Li ◽  
Yoshiki Kubota ◽  
Masahiko Okamoto ◽  
Shintaro Shiba ◽  
Shohei Okazaki ◽  
...  

Abstract Background Daily anatomical deviations may distort the dose distribution in carbon ion radiotherapy (CIRT), which may cause treatment failure. Therefore, this study aimed to perform re-planning to maintain the dose coverage in patients with pancreatic cancer with passive scattering CIRT. Methods Eight patients with pancreatic cancer and 95 daily computed tomography (CT) sets were examined. Two types of adaptive plans based on new range compensators (RCs) (AP-1) and initial RCs (AP-2) were generated. In AP-2, each beam was optimized by manually adjusting the range shifter thickness and spread-out Bragg peak size to make dose reduction by < 3% of the original plan. Doses of the original plan with bone matching (BM) and tumor matching (TM) were examined for comparison. We calculated the accumulated dose using the contour and intensity-based deformable image registration algorithm. The dosimetric differences in respect to the original plan were compared between methods. Results Using TM and BM, mean ± standard deviations of daily CTV V95 (%) difference from the original plan was − 5.1 ± 6.2 and − 8.8 ± 8.8, respectively, but 1.2 ± 3.4 in AP-1 and − 0.5 ± 2.1 in AP-2 (P < 0.001). AP-1 and AP-2 enabled to maintain a satisfactory accumulated dose in all patients. The dose difference was 1.2 ± 2.8, − 2,1 ± 1.7, − 7.1 ± 5.2, and − 16.5 ± 15.0 for AP-1, AP-2, TM, and BM, respectively. However, AP-2 caused a dose increase in the duodenum, especially in the left–right beam. Conclusions The possible dose deterioration should be considered when performing the BM, even TM. Re-planning based on single beam optimization in passive scattering CIRT seems an effective and safe method of ensuring the treatment robustness in pancreatic cancer. Further study is necessary to spare healthy tissues, especially the duodenum.


2020 ◽  
Vol 152 ◽  
pp. S308
Author(s):  
M. Boekhoff ◽  
I. Defize ◽  
A. Kotte ◽  
N. Takahashi ◽  
J. Lagendijk ◽  
...  

2021 ◽  
Vol 161 ◽  
pp. S428-S429
Author(s):  
Y. Ez-zyouy ◽  
A. Gulyban ◽  
C. Bouchart ◽  
N. Reynaert

2018 ◽  
Vol 63 (12) ◽  
pp. 125005 ◽  
Author(s):  
Yibing Wang ◽  
Steven F Petit ◽  
Eliana Vásquez Osorio ◽  
Vikas Gupta ◽  
Alejandra Méndez Romero ◽  
...  

Author(s):  
N Singh ◽  
Sh Ahamed ◽  
A Sinha ◽  
Sh Srivastava ◽  
N K Painuly ◽  
...  

Background: Intracavitary brachytherapy plays a major role in management of cervical carcinoma. Assessment of dose received by OAR’s therefore becomes crucial for the estimation of radiation toxicities in high dose rate brachytherapy.Objective: The purpose of this study is to evaluate the role of in vivo dosimetry in HDR brachytherapy and to compare the actual doses delivered to OAR’s with those calculated during treatment planning.Materials and Methods: A total of 50 patients were treated with Microselectron HDR. Out of 50 patients, 26 were treated with a dose of 7 Gy and 24 with a dose of 9 Gy, prescribed to point A. Brachytherapy planning and evaluation of dose to the bladder and rectum was done on TPS & in vivo dosimetry was performed using portable MOSFET.Results: The calibration factors calculated for both the dosimeters are almost equal and are 0.984 cGy/mV and 1.0895 cGy/mV. For bladder, dose deviation was found to be within +/- 5% in 28 patients, +/- 5-10% in 14 patients, +/- 10-15% in 4 patients. The deviation between the TPS-calculated dose and the dose measured by MOSFET for rectum was within +/- 5% in 31 patients, +/- 5–10% in 8 patients, and +/- 10–15% in 7 patients.Conclusion: TPS calculated doses were slightly higher than that measured by MOSFET. The use of a small size of MOSFET dosimeter is an efficient method for accurately measuring doses in high-dose gradient fields typically seen in brachytherapy. Therefore, to reduce risk of large errors in the dose delivery, in vivo dosimetry can be done in addition to TPS computations.


2016 ◽  
Vol 119 (2) ◽  
pp. 319-325 ◽  
Author(s):  
Antonetta C. Houweling ◽  
Kyohei Fukata ◽  
Yoshiki Kubota ◽  
Hirofumi Shimada ◽  
Coen R.N. Rasch ◽  
...  

2017 ◽  
Vol 123 ◽  
pp. S471-S472
Author(s):  
V.C. Hamming ◽  
C.L. Brouwer ◽  
M.J. Van Goethem ◽  
R.I. Jolck ◽  
C. Van Leijsen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document